ArticleFrontiers in oncology2021
Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.Frontiers in immunology · 2025Pooled it
- Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis.Annals of medicine · 2023Pooled it
- Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis.Clinical and experimental medicine · 2022Pooled it
- Pooled it
- Dynamic systemic immune-inflammation index predicts survival after neoadjuvant immunotherapy in gastric cancer: A multicenter study.iScience · 2026Article
- Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer.World journal of gastrointestinal oncology · 2026Article
- Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring.Frontiers in immunology · 2026Review
- Impact of body mass index on progression-free survival and endocrine immune-related adverse events in advanced NSCLC patients treated with nivolumab: A retrospective cohort study.Northern clinics of Istanbul · 2026Article
- Perioperative changing patterns of systemic immune-inflammatory index (SII) and outcomes in stage I-III non-small cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies.Frontiers in immunology · 2025Review
- Integration of Delta-Radiomics Features and Inflammatory Biomarkers for Neoadjuvant Chemo-Immunotherapy Efficacy in Locally Advanced Esophageal Squamous Cell Carcinoma.Journal of inflammation research · 2025Article
- Hematological ratios, immune-related adverse events and mortality in patients treated with immune checkpoint inhibitors.PloS one · 2025Article
- Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.Cancer immunology, immunotherapy : CII · 2024Article
- Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours.Clinical and translational medicine · 2024Review
- Prognostic significance of serum Chemerin and neutrophils levels in patients with oral squamous cell carcinoma.Heliyon · 2024Article
- High Systemic Immune-Inflammation Index Values Before Treatment Predict Poor Pancreatic Cancer Outcomes After Definitive Chemoradiotherapy.Clinical Medicine Insights. Oncology · 2024Article
- Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors.Therapeutic advances in medical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of current treatment regimens for pancreatic cancer (PC) remains unsatisfactory. In recent years, immune checkpoint blockade (ICB) therapy has shown promising anti-tumor outcomes in many malignancies, including PC. Inexpensive and readily available biomarkers which predict therapeutic responses and prognosis are in critical need. Systemic immune-inflammation index (SII) and neutrophil-lymphocyte ratio (NLR) are emerging predictors for prognosis of various tumors. We aim to investigate the prognostic significance of baseline SII, NLR, and their changes in PC patients treated with ICB. Our retrospective analysis included PC patients treated with ICB therapy in the Chinese PLA General Hospital. All demographic, biological, and clinical data were extracted from medical records. Relative changes of SII after two doses of ICB were defined as ΔSII% and calculated as (SII
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.